Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H48O6.C4H11NO2 |
| Molecular Weight | 621.8449 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCNCCO.C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]3(C)[C@H]2[C@H](O)C[C@H]4\C([C@H](C[C@]34C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O
InChI
InChIKey=OQZZCXRLEFBPLZ-JCJNLNMISA-N
InChI=1S/C31H48O6.C4H11NO2/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32;6-3-1-5-2-4-7/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36);5-7H,1-4H2/b26-20-;/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-;/m0./s1
| Molecular Formula | C31H48O6 |
| Molecular Weight | 516.7092 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C4H11NO2 |
| Molecular Weight | 105.1356 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014-01 |
|
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | 2013-12 |
|
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013-11 |
|
| Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. | 2013-11 |
|
| Canine ocular thelaziosis caused by Thelazia callipaeda in Portugal. | 2013-07 |
|
| Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | 2010-12 |
|
| Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid. | 2010-06 |
|
| Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. | 2009-04 |
|
| A case of recurrent rapidly progressive lower limb weakness. | 2008-07 |
|
| Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. | 2008-03 |
|
| Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. | 2006-08 |
|
| Sideroblastic anaemia during fusidic acid treatment. | 2004-05 |
|
| Sideroblastic anaemia and fusidic acid. | 2003-02 |
|
| Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. | 2002-07-01 |
|
| [Cholestatic icterus induced by the administration of fusidic acid in a cirrhotic patient]. | 2002-06-29 |
|
| Hypocalcaemia during fusidic acid therapy. | 2002-02 |
|
| In vitro susceptibility of Mycobacterium tuberculosis to fusidic acid. | 2001-12 |
|
| Antimycobacterial plant terpenoids. | 2001-11 |
|
| Acute renal failure in association with fusidic acid. | 1997-06 |
|
| Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. | 1997-05 |
|
| Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages. | 1994-05-01 |
|
| Acute renal failure following intravenous fusidic acid. | 1993 |
|
| Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. | 1992-08 |
|
| Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp. | 1990-09 |
|
| Susceptibility of mycobacteria to fusidic acid. | 1990-04 |
|
| Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. | 1989-01 |
|
| Suppression of HIV replication in vitro by fusidic acid parallels cell toxicity. | 1989-01 |
|
| Inhibition of HIV replication in vitro by fusidic acid. | 1987-10-10 |
|
| Fusidic acid-induced hyperbilirubinemia. | 1987-08 |
|
| Screening for new compounds with antiherpes activity. | 1984-10 |
|
| Staphylococcal septicaemia complicated by probable cloxacillin neurotoxicity and by jaundice induced by fusidic acid. | 1983-04 |
|
| Adverse reactions to intravenous administration of fusidic acid. | 1981 |
|
| Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains. | 1973-09 |
|
| Haematuria during methicillin therapy. | 1971-07 |
|
| Fusidic acid: a new antibiotic. | 1962-03-10 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:10:50 GMT 2025
by
admin
on
Mon Mar 31 20:10:50 GMT 2025
|
| Record UNII |
1XKK7J9CT6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000079554
Created by
admin on Mon Mar 31 20:10:50 GMT 2025 , Edited by admin on Mon Mar 31 20:10:50 GMT 2025
|
PRIMARY | |||
|
1XKK7J9CT6
Created by
admin on Mon Mar 31 20:10:50 GMT 2025 , Edited by admin on Mon Mar 31 20:10:50 GMT 2025
|
PRIMARY | |||
|
240-442-3
Created by
admin on Mon Mar 31 20:10:50 GMT 2025 , Edited by admin on Mon Mar 31 20:10:50 GMT 2025
|
PRIMARY | |||
|
SUB13572MIG
Created by
admin on Mon Mar 31 20:10:50 GMT 2025 , Edited by admin on Mon Mar 31 20:10:50 GMT 2025
|
PRIMARY | |||
|
C013483
Created by
admin on Mon Mar 31 20:10:50 GMT 2025 , Edited by admin on Mon Mar 31 20:10:50 GMT 2025
|
PRIMARY | |||
|
16391-75-6
Created by
admin on Mon Mar 31 20:10:50 GMT 2025 , Edited by admin on Mon Mar 31 20:10:50 GMT 2025
|
PRIMARY | |||
|
46174083
Created by
admin on Mon Mar 31 20:10:50 GMT 2025 , Edited by admin on Mon Mar 31 20:10:50 GMT 2025
|
PRIMARY | |||
|
DTXSID701020012
Created by
admin on Mon Mar 31 20:10:50 GMT 2025 , Edited by admin on Mon Mar 31 20:10:50 GMT 2025
|
PRIMARY | |||
|
22971
Created by
admin on Mon Mar 31 20:10:50 GMT 2025 , Edited by admin on Mon Mar 31 20:10:50 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
